These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11363056)

  • 1. To treat or not to treat--approaches to antiretroviral therapy. Interview by Anthony J. Japour.
    Coombs R; Cotton D; Hammer S; Saag M; van der Horst C
    AIDS Clin Care; 1996 Jan; 8(1):1-4. PubMed ID: 11363056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ACTG 175 and Delta.
    Torres G
    GMHC Treat Issues; 1995 Oct; 9(10):2-3. PubMed ID: 11362915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies confirm value of early and combination treatments.
    Vazquez E
    Posit Aware; 1995; VI(6):8. PubMed ID: 11363148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue.
    Mathé G; Pontiggia P; Orbach-Arbouys S; Triana K; Ambetima N; Morette C; Hallard M; Blanquet D
    Biomed Pharmacother; 1996; 50(5):220-7. PubMed ID: 8949403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study results at a glance.
    AIDS Alert; 1995 Nov; 10(11):134. PubMed ID: 11362922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies of zidovudine in combination with didanosine and zalcitabine.
    Jablonowski H
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New trials reach same conclusion: two drugs are better than AZT alone.
    AIDS Alert; 1995 Nov; 10(11):133-6. PubMed ID: 11362921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AZT delta study: major European/Australian study finds combinations better than AZT alone.
    King E
    AIDS Treat News; 1995 Oct; (no 232):3-4. PubMed ID: 11362876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy increases survival.
    Treat Rev; 1995 Nov; (no 20):2-3. PubMed ID: 11363019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AZT studies reinforce benefits of combination.
    AIDS Alert; 1995 Jan; 10(1):11-2. PubMed ID: 11362167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AZT, ddI, and ddC combinations at FDA advisory hearing. Food and Drug Administration.
    James JS
    AIDS Treat News; 1996 Apr; (no 244):6. PubMed ID: 11363307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Closing the circle on HIV--or not.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1995 Oct; 1(9):10-4, 17-29 contd. PubMed ID: 11362964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Top AIDS researchers' strategy for antiretroviral treatment.
    AIDS Alert; 1996 Sep; 11(9):97-100. PubMed ID: 11363728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Researchers are rethinking role of AZT in drug therapy.
    AIDS Policy Law; 1995 Oct; 10(18):11. PubMed ID: 11362821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can the conundrums of ACTG 175 be solved? An interview with Martin S. Hirsch, MD.
    Hirsch MS
    J Int Assoc Physicians AIDS Care; 1995 Oct; 1(9):29-30. PubMed ID: 11362965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits of combination therapy confirmed.
    Cheng B
    PI Perspect; 1995 Dec; (no 17):3-4. PubMed ID: 11363111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3TC approval may revive AZT's appeal.
    Vazquez E
    Posit Aware; 1996; 7(1):8-9. PubMed ID: 11363136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Making sense of 175 and Delta.
    Smart T
    GMHC Treat Issues; 1995 Oct; 9(10):4. PubMed ID: 11362916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACTG 175: new insights into treating patients with intermediate-stage HIV disease.
    Folkers G
    NIAID AIDS Agenda; 1995 Dec; ():4-5. PubMed ID: 11363352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Major protease inhibitor triple combination trial begins soon: CD4 under 200, AZT experienced, 3TC naive.
    James JS
    AIDS Treat News; 1995 Dec; (no 237):3. PubMed ID: 11363075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.